A 34‐year‐old man with non‐obstructive apical hypertrophic cardiomyopathy (RCD code: III‐2A.1)

Ewa Dziewięcka, Paweł Rubiś, Sylwia Wiśniowska-Śmiałek, Katarzyn Holcman, Agata Leśniak-Sobelga, Marta Hlawaty, Magdalena Kostkiewicz, Piotr Podolec

Full Text:

PDF

Abstract


Hypertrophic cardiomyopathy (HCM) is a primary disease of the myocardium that is defined by the presence of regional (more frequent) or global myocardial hypertrophy, which usually results in functional cardiac impairment. We present a case of a 34-year-old man with apical HCM who was admitted to the cardiology department due to cardiac hypertrophy in the echocardiogram. The management of HCM patients is directed at heart failure treatment and decreasing left ventricular outflow tract or intraventricular gradient, if present. According to the patient’s calculated 5-year mortality risk, assessed using the HCM Risk-SCD Calculator, indications for implantation of an implantable cardioverter defibrillator were evaluated. JRCD 2017; 3 (5): 180–183

Keywords


myocardial thickening; echocardiography; magnetic resonance imaging; electrocardiogram; rare disease

References


Kitaoka H, Doi Y, Casey SA, et al. Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol. 2003; 92: 1183–1186.

Hada Y, Sakamoto T, Amano K, et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am J Cardiol 1987; 59: 183–184.

Savage DD, Castelli WP, Abbott RD, et al. Hypertrophic cardiomyopathy and its markers in the general population: the great masquerader revisited: the Framingham Study. J Cardiovasc Ultrason 1983; 2: 41–47.

Maron BJ, Peterson EE, Maron MS, et al. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. Am J Cardiol. 1994; 73: 577–580.

Podolec P, Kabłak-Ziembicka A, Komar M, et al. Rare Cardiovascular Diseases. From classification to clinical examples. Medycyna Praktyczna 2013; 205–209.

Cirino AL; Ho, C. Hypertrophic Cardiomyopathy Overview. GeneReviews 2008.

Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54: 201–211.

Elliot PM, Anderson B, Arbustini A, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2007; 29: 270–277.

Yusuf SW, Bathina JD, Banchs J, et al. Apical hypertrophic cardiomyopathy. World Journal of Cardiology. 2011; 3: 256–259.

Maron MS, Olivotto I, Harrigan C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011; 124: 40–47.

Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003; 42: 1687–1713.

Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000; 36: 2212–2218.

Eriksson MJ, Sonnenberg B, Woo A, et al. Long -term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39: 638–645.

Arad M, Penas-Lado M, Monserrat L, et al. Gene mutations in apical hypertrophic cardiomyopathy. Circulation 2005; 112: 2805–2811.

Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000; 102: 858–864.

Elliott PM, Anastasakis A, Borger MA, et al. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35: 2733–2779.

Rubiś P, Biernacka-Fijałkowska B, Khachatryan L, et al. Comparison of two European models estimating risk of sudden cardiac death in hypertrophic cardiomyopathy. Acta Cardiologica 2017; 72: 446–452.




DOI: http://dx.doi.org/10.20418%2Fjrcd.vol3no5.296

Refbacks

  • There are currently no refbacks.
Journal of Rare Cardiovascular Diseases (JRCD)
John Paul II Hospital in Kraków, 80 Prądnicka Str., 31-202 Kraków, Poland
Phone: +48 (12) 614 33 99, +48 (12) 614 34 88 Fax: +48 (12) 614 34 88
e-mail: rarediseases@szpitaljp2.krakow.pl
Published by SoftQ sp. z o.o.
ul. Oleandry 2, 30-063 Kraków, Poland
Phone: +48 (12) 444 1650 Fax: +48 (12) 444 1659
e-mail: softq@softq.pl